Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company focused on cardiovascular disease and the development and commercialization of icosapent ethyl, marketed as VASCEPA in the United States and other regions and as VAZKEPA in Europe. The AMRN news feed on Stock Titan brings together Amarin’s press releases and related coverage so investors can follow how the company is executing on its cardiovascular strategy.
News about Amarin frequently covers clinical and scientific developments around its REDUCE-IT cardiovascular outcomes trial and subsequent post hoc analyses, including presentations at major conferences such as the American Heart Association Scientific Sessions, the European Society of Cardiology Congress and the Canadian Cardiovascular Congress. These updates often explore cardiovascular risk reduction in high-risk subgroups, mechanistic insights into eicosapentaenoic acid, and evolving guideline and regulatory perspectives on triglyceride-lowering therapies.
Investors can also expect regular updates on Amarin’s commercial performance and operating model. Recent releases have discussed the transition to a fully partnered international commercialization strategy, an exclusive long-term license and supply agreement with Recordati to commercialize VAZKEPA across 59 European-focused countries, restructuring efforts to reduce operating expenses, and commentary on market dynamics for therapies targeting elevated triglycerides and severe hypertriglyceridemia.
Regulatory and policy developments are another recurring theme, including Amarin’s statements on FDA labeling changes for fenofibrate products and the implications for cardiovascular risk management. Together, these categories of news provide a view into how Amarin positions VASCEPA/VAZKEPA within global cardiovascular care, how its partnerships evolve, and how scientific data may influence future prescribing patterns. Bookmark this page to monitor AMRN news on clinical data, partnerships, financial updates and regulatory developments in one place.
Amarin (NASDAQ: AMRN) highlighted a post hoc REDUCE-IT analysis published March 2026 in the European Journal of Preventive Cardiology showing icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost to hospitalization and death among 8,179 statin-treated participants followed for a median of five years.
The paper underscores patient-centered benefits of IPE (VASCEPA/VAZKEPA) and notes prior REDUCE-IT results influenced guideline inclusion.
Amarin (NASDAQ: AMRN) reported Q4 and full‑year 2025 results showing operational improvements and a tighter cost base. Total net revenue was $49.2M in Q4 (down 21% YoY); operating loss narrowed to $6.3M; cash and investments were $302.6M with no debt.
The company realized $31M of targeted $70M cost savings and recorded $36.2M of restructuring charges in 2025, with remaining charges expected in early 2026. The company finalized a long‑term European license and supply agreement for VAZKEPA and retained U.S. VASCEPA market leadership.
Amarin (NASDAQ: AMRN) used American Heart Month (Feb 23, 2026) to urge urgent action on underutilized, guideline‑supported cardiovascular therapies.
The company highlighted that 48.9% of U.S. adults live with CVD and cited evidence that cumulative CV event incidence can reach ~40% over 10 years, calling to “Review, Reassess, Refocus” care to close treatment gaps.
Amarin (NASDAQ: AMRN) will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A pre-market press release will be issued, followed by a conference call with senior management at 8:00 a.m. ET.
Investors can join via telephone (US: 888-506-0062; international: 973-528-0011, access code 675507) or via webcast on the company Investor Relations website. A replay will be available online and by phone through August 25, 2026.
Amarin (NASDAQ: AMRN) commented on recent therapeutic advances for patients with elevated triglycerides and said its VASCEPA/VAZKEPA (icosapent ethyl) franchise is well positioned to benefit from broader category commercialization. The company noted VASCEPA has been prescribed >25 million times, is FDA approved for severe hypertriglyceridemia (TG ≥500 mg/dL) and for cardiovascular risk reduction as an adjunct to statin therapy, and cited REDUCE-IT results showing a 25% relative reduction in cardiovascular events in 8,179 patients. Amarin also highlighted a 2025 exclusive license with Recordati for commercialization across 59 countries, with VAZKEPA available in >20 countries.
Amarin (NASDAQ:AMRN) reported preliminary unaudited 2025 results and operational milestones, highlighting a year-end cash balance of $303 million, positive cash flow in Q4 2025 achieved ahead of prior expectations, and a debt-free balance sheet. The company realized ~50% of an estimated $70 million OPEX savings from its 2025 restructuring and expects the full savings by June 30, 2026. FY 2025 net revenue is expected to be $212–$217 million, with Q4 revenue of $48–$53 million. Amarin completed a long-term exclusive license and supply agreement with Recordati for VAZKEPA in 59 countries and secured regulatory approvals in South Korea and Singapore.
Amarin (NASDAQ: AMRN) presented a new REDUCE-IT post hoc aspirin analysis at AHA Scientific Sessions 2025 showing that icosapent ethyl significantly reduced cardiovascular events in high-risk, statin-treated patients with elevated triglycerides.
Among 8,179 participants (6,179 on aspirin), icosapent ethyl cut the primary endpoint by 28% in aspirin users (P<0.0001), with an absolute risk reduction 5.9% and NNT 17. Total primary events were reduced by 36% (RR 0.64; 95% CI 0.56–0.74). In the secondary prevention aspirin subgroup (n=4,867) total events fell 39% (RR 0.61; 95% CI 0.53–0.70).
The analysis found consistent benefit with or without aspirin and reported a safety profile in aspirin users consistent with the overall trial population.
Amarin (NASDAQ: AMRN) will present new analyses and mechanistic studies at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025.
Highlighted items include REDUCE-IT analyses of icosapent ethyl (VASCEPA/VAZKEPA) assessing cardiovascular outcomes with or without baseline aspirin use, plus mechanistic data on EPA effects on lipoprotein(a) oxidation, anti-inflammatory actions, and endothelial protection. Specific presentations are scheduled Nov 9–10, 2025, across Abstract Board, Population Science, and Basic Science zones.
Amarin (NASDAQ: AMRN) reported Q3 2025 results showing a shift toward a fully partnered international commercial model and initial margin improvement after a June 2025 global restructuring.
Key Q3 2025 metrics: Total net revenue $49.7M (+17% YoY), Product revenue $48.6M (+16% YoY) driven by U.S. product revenue $40.9M (+34% YoY). Operating loss narrowed to $11.1M (operating margin -22%) from $25.2M year-ago. Net loss was $7.7M ($0.02/share). SG&A fell 47%; restructuring charges of $9.4M were recorded. Cash and investments totaled $286.6M and the company is debt free, targeting sustainable positive free cash flow in 2026.
Amarin (NASDAQ:AMRN) praised the FDA for updating fenofibrate labeling on Oct 27, 2025, to state a lack of cardiovascular benefit and to add safety language and a narrowed indication.
The label cites two large diabetes trials and PROMINENT, and warns of increased rhabdomyolysis risk when fibrates are combined with statins. The release notes >11 million US fibrate prescriptions in 2023, >60% co-prescribed with statins, and ~2 million fibrate patients in Western Europe.
Amarin said the change should shift prescribing toward FDA-approved, outcome-proven therapies such as VASCEPA (icosapent ethyl).